Global Cold Agglutinin Disease Market Size study, By Drugs (Corticosteroids, Alkylating Agents, Purine Nucleoside Analogs, Biologics, Others), By Dosage Form (Tablets, Injections, Others), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), and

Global Cold Agglutinin Disease Market Size study, By Drugs (Corticosteroids, Alkylating Agents, Purine Nucleoside Analogs, Biologics, Others), By Dosage Form (Tablets, Injections, Others), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), and Regional Forecasts 2022-2028

Global Cold Agglutinin Disease Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Cold agglutinin disease (CAD) is a variety of autoimmune hemolytic anemia (AIHA). In this condition, the individual’s immune system attacks and destroys their own red blood cells (RBCs) because of the higher exposure to cold temperatures. The increasing number of geriatric people, rising incidences of cold agglutinin disease, and growing healthcare expenditure are major factors fueling the market demand across the globe. For instance, according to the Department of Economic and Social Affairs, in 2019, the world's population of people aged 65 and up totaled 703 million. Also, the number of elderly people is expected to increase to 1.5 billion by 2050. Accordingly, the increasing number of aged people are more likely to suffer from Cold Agglutinin Disease, which, in turn, bolsters the growth of the global market. However, the shortage of skilled professionals and lack of healthcare infrastructure in emerging regions impede the growth of the market over the forecast period of 2022-2028. Also, an increase in the number of drug approvals and launches and growing investment in the development of advanced technologies are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global Cold Agglutinin Disease Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the increasing healthcare expenditure, the presence of various prominent market players, and growing investment in R&D activities. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the increasing patient pool, as well as availability of better healthcare facilities, would create lucrative growth prospects for the Cold Agglutinin Disease Market across the Asia-Pacific region.

Major market players included in this report are:
Sanofi
Pfizer Inc.
GlaxoSmithKline plc
Novartis AG
Zydus Cadila
AstraZeneca
Johnson & Johnson
Bayer AG
Sun Pharmaceutical Industries Ltd.
Apellis Pharmaceuticals

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drugs:
Corticosteroids
Alkylating Agents
Purine Nucleoside Analogs
Biologics
Others
By Dosage Form:
Tablets
Injections
Others
By End-Users:
Hospitals
Specialty Clinics
Homecare
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Cold Agglutinin Disease Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


Companies Mentioned

Sanofi
Pfizer Inc.
GlaxoSmithKline plc
Novartis AG
Zydus Cadila
AstraZeneca
Johnson & Johnson
Bayer AG
Sun Pharmaceutical Industries Ltd.
Apellis Pharmaceuticals

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.